Kura Oncology (NASDAQ:KURA) Earns “Buy” Rating from HC Wainwright

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $32.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 82.75% from the company’s previous close.

A number of other brokerages have also recently weighed in on KURA. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. Wedbush reaffirmed an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Friday, August 9th. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and decreased their target price for the company from $26.00 to $19.00 in a report on Monday, October 14th. JMP Securities restated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a report on Monday, August 12th. Finally, StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.83.

Kura Oncology Trading Down 1.5 %

KURA opened at $17.51 on Thursday. Kura Oncology has a 52 week low of $7.52 and a 52 week high of $24.17. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02. The business has a fifty day simple moving average of $19.34 and a 200-day simple moving average of $20.09. The firm has a market cap of $1.34 billion, a P/E ratio of -7.85 and a beta of 0.84.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.53) EPS. On average, equities analysts expect that Kura Oncology will post -2.46 earnings per share for the current year.

Institutional Trading of Kura Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after acquiring an additional 28,212 shares in the last quarter. Avoro Capital Advisors LLC increased its stake in Kura Oncology by 29.2% in the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after purchasing an additional 870,000 shares during the last quarter. Armistice Capital LLC raised its holdings in Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after purchasing an additional 302,000 shares in the last quarter. Artal Group S.A. raised its holdings in Kura Oncology by 8.6% during the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock worth $40,951,000 after purchasing an additional 151,828 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of Kura Oncology by 50.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after buying an additional 577,732 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.